First National Bank of Omaha Sells 33,110 Shares of Abbott Laboratories $ABT

First National Bank of Omaha trimmed its position in Abbott Laboratories (NYSE:ABT) by 19.2% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 139,704 shares of the healthcare product maker’s stock after selling 33,110 shares during the period. First National Bank of Omaha’s holdings in Abbott Laboratories were worth $12,736,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the company. Fidelity National Financial Inc. purchased a new stake in shares of Abbott Laboratories during the second quarter valued at approximately $20,235,000. Alpine Woods Capital Investors LLC boosted its position in Abbott Laboratories by 1,199.3% in the second quarter. Alpine Woods Capital Investors LLC now owns 43,202 shares of the healthcare product maker’s stock worth $3,920,000 after purchasing an additional 39,877 shares during the last quarter. Meeder Advisory Services Inc. grew its stake in Abbott Laboratories by 3.3% in the 2nd quarter. Meeder Advisory Services Inc. now owns 35,510 shares of the healthcare product maker’s stock valued at $3,222,000 after purchasing an additional 1,149 shares during the period. Harborfront Financial Group LLC bought a new position in Abbott Laboratories in the 2nd quarter valued at $84,000. Finally, Citizens Financial Group Inc. RI increased its position in shares of Abbott Laboratories by 3.9% during the 2nd quarter. Citizens Financial Group Inc. RI now owns 129,702 shares of the healthcare product maker’s stock valued at $11,769,000 after purchasing an additional 4,897 shares during the last quarter. Institutional investors own 75.18% of the company’s stock.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: The FDA approved Abbott’s Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for diabetes patients age two and older. The wearable is the first of its kind to track both glucose and ketones, strengthening Abbott’s position in diabetes care and creating potential for future integration with insulin-pump systems. FDA Approves Abbott’s First Wearable Device for Dual Ketone and Glucose Tracking
• Positive Sentiment: Abbott received the European CE Mark for its next-generation Amulet 360 left atrial appendage occluder. The device is designed to reduce stroke risk in certain atrial-fibrillation patients and may reduce reliance on blood-thinning medication, supporting growth in Abbott’s structural-heart business. Abbott’s next-generation Amulet 360 device receives CE Mark
• Positive Sentiment: Analyst coverage remains supportive, with TD Cowen expecting Abbott’s stock to rise. Separately, Zacks highlighted ABT as a strong long-term momentum candidate, suggesting improving price trends and investor interest despite its premium valuation. TD Cowen Analyst Says Abbott Stock Price Expected to Rise
• Neutral Sentiment: Abbott’s latest reported quarter exceeded consensus estimates, with earnings and revenue growing year over year. Management’s 2026 earnings guidance also points to continued expansion, but ABT’s elevated price-to-earnings ratio leaves the stock sensitive to execution and valuation concerns.
• Negative Sentiment: Recent coverage noted that Abbott shares fell 2.2% in the prior session even as the broader market advanced, reflecting near-term underperformance and possible profit-taking. The stock remains well below its 12-month high, so investors may want evidence that the new devices translate into meaningful sales growth. Abbott Stock Sinks as Market Gains

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on ABT shares. Robert W. Baird assumed coverage on shares of Abbott Laboratories in a research note on Wednesday, July 1st. They issued an “outperform” rating and a $121.00 target price on the stock. Bank of America lowered their price target on shares of Abbott Laboratories from $120.00 to $102.00 in a report on Friday, June 12th. The Goldman Sachs Group dropped their price objective on Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating on the stock in a research note on Wednesday, May 27th. Royal Bank Of Canada restated an “outperform” rating and issued a $130.00 target price on shares of Abbott Laboratories in a research note on Friday, July 17th. Finally, Citigroup upped their price target on Abbott Laboratories from $108.00 to $112.00 and gave the company a “buy” rating in a research report on Friday, July 17th. Three research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and an average price target of $119.50.

Abbott Laboratories Trading Up 0.9%

NYSE:ABT opened at $112.63 on Friday. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $137.49. The company has a 50-day moving average price of $102.61 and a 200-day moving average price of $100.22. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. The stock has a market cap of $194.89 billion, a price-to-earnings ratio of 36.45, a P/E/G ratio of 2.16 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.28 by $0.03. The business had revenue of $12.59 billion for the quarter, compared to analysts’ expectations of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The firm’s quarterly revenue was up 13.0% on a year-over-year basis. During the same period in the prior year, the firm posted $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Equities analysts predict that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th were issued a dividend of $0.63 per share. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.2%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 81.55%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.